Research & Development
AnchorDx enrolling U.S. clinical trial for bladder cancer assay
The study, which will enroll more than 1,000 participants, aims to evaluate the noninvasive, qPCR assay which detects two DNA methylation biomarkers in urine specimens from patients suspected of having bladder cancer.
November 23, 2022
Nucleix announces CLIA certification, CAP accreditation for San Diego laboratory
Nucleix announced that it has received CLIA certification and CAP accreditation for its San Diego-based clinical laboratory.
October 19, 2022
Predicine to present posters on liquid biopsy tech at ESMO
Predicine's liquid biopsy portfolio includes assays that provide translational insights to aid in potential cancer therapeutic strategies.
September 8, 2022
Nanostics launches bladder cancer study
Its ClarityDX bladder test uses extracellular vesicle detection technology and machine-learning model analysis to identify the most potent disease predictors for the early detection of bladder cancer.
July 19, 2022
Nucleix expands EU label for bladder cancer test
Initially, the technology was indicated for the monitoring of tumor recurrence in conjunction with cystoscopy in patients previously diagnosed with bladder cancer.
June 21, 2022
Nonagen Bioscience secures CE Mark for bladder cancer test
The urine test detects 10 biomarkers associated with bladder cancer, the company said.
June 16, 2022
Genetic causes identified for three rare diseases
Researchers in study validate test to identify newborns with homocystinuria, a rare inherited disease
SARS-CoV-2 infection weakens immune-cell response to vaccination, study suggests
Duke University researchers discover biomarkers may identify early pancreatic cancer risk
Chembio CEO urges stockholders to tender remaining shares as deadline is extended for acquisition
Cue Health Q4 revenues decline 24% as firm expands, diversifies POC test menu
Paige, Janssen collaborating on AI-based bladder cancer test
Developed by Janssen, the test is a first-of-its-kind screening tool to predict the occurrence of actionable genomic alterations, Paige said.
June 14, 2022
Bio-Techne, Nonangen enter into agreement for Oncuria
The companies said they are targeting the last quarter of calendar year 2022 to make Oncuria available as a laboratory-developed test.
May 12, 2022
Guardant highlights data on multicancer test at AACR 2022
Guardant Shield analyzes about 20,000 epigenomic markers with a single blood test. In the data presented at AACR 2022, researchers showed the efficacy of Guardant Shield in the detection of four types of early-stage cancers: colorectal, lung, pancreatic, and bladder.
April 12, 2022
ASCO study touts data from bladder cancer clinical trial
The identification of a biomarker for predicting bladder cancer survival comes out the secondary part of the S1314 clinical trial, which measured long-term survival data in patients with muscle-invasive bladder cancer being treated with cisplatin-based chemotherapy before surgery.
February 13, 2022
AnchorDx bladder cancer test gets FDA 'breakthrough' designation
The test, UriFind, received the first breakthrough designation granted to a company in China for a liquid biopsy test for bladder cancer detection. The test is as accurate as a cystoscopy and significantly better than exfoliative cytology and fluorescence in situ hybridization (FISH) in detecting early and nonmuscle-invasive bladder cancer, according to the company.
July 20, 2021
Natera and BGI launch new assay in China
The Signatera assay was tested in studies in nonsmall cell lung, bladder, breast, and colorectal cancers and identifies MRD up to two years earlier than standard imaging, the companies said in a release.
June 23, 2021
Page 1 of 2